前沿生物跌16.34% A股募20亿瑞银证券保荐上市

Company Overview - Frontline Bio (688221.SH) closed at 15.82 yuan, experiencing a decline of 16.34%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance, at a price of 20.50 yuan per share [1] - The highest stock price recorded since listing was 35.53 yuan on the first day of trading [1] Fundraising and Financials - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company aimed to raise 200.085 million yuan for various projects, including clinical research for HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [1] - The total issuance costs (excluding VAT) for the initial public offering were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Strategic Participation - UBSAG, the sponsoring institution, participated in the strategic placement of the issuance, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for an amount of approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is set for 24 months from the date of listing [2] Additional Issuance - On September 22, 2022, Frontline Bio announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [3] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [3] - The total fundraising from the two issuances amounts to approximately 2.044 billion yuan [4]